It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Endoplasmic reticulum (ER)-associated degradation (ERAD) and ER-phagy are two principal degradative mechanisms for ER proteins and aggregates, respectively; however, the crosstalk between these two pathways under physiological settings remains unexplored. Using adipocytes as a model system, here we report that SEL1L-HRD1 protein complex of ERAD degrades misfolded ER proteins and limits ER-phagy and that, only when SEL1L-HRD1 ERAD is impaired, the ER becomes fragmented and cleared by ER-phagy. When both are compromised, ER fragments containing misfolded proteins spatially coalesce into a distinct architecture termed Coalescence of ER Fragments (CERFs), consisted of lipoprotein lipase (LPL, a key lipolytic enzyme and an endogenous SEL1L-HRD1 substrate) and certain ER chaperones. CERFs enlarge and become increasingly insoluble with age. Finally, we reconstitute the CERFs through LPL and BiP phase separation in vitro, a process influenced by both redox environment and C-terminal tryptophan loop of LPL. Hence, our findings demonstrate a sequence of events centered around SEL1L-HRD1 ERAD to dispose of misfolded proteins in the ER of adipocytes, highlighting the profound cellular adaptability to misfolded proteins in the ER in vivo.
Endoplasmic reticulum (ER)-associated degradation (ERAD) and ER-phagy are two central degradative mechanisms in the ER. Here the authors describe the sequence of events underlying the disposition of misfolded ER proteins by ERAD and ER-phagy.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details




1 University of Michigan Medical School, Department of Molecular & Integrative Physiology, Ann Arbor, USA (GRID:grid.214458.e) (ISNI:0000000086837370)
2 Tsinghua University, Tsinghua-Peking Center for Life Science, IDG/McGovern Institute for Brain Research, School of Life Sciences, Beijing, China (GRID:grid.12527.33) (ISNI:0000 0001 0662 3178)
3 University of Michigan, College of Engineering and Michigan Center for Materials Characterization, Ann Arbor, USA (GRID:grid.214458.e) (ISNI:0000000086837370)
4 Northwestern University Feinberg School of Medicine, Department of Pathology, Chicago, USA (GRID:grid.16753.36) (ISNI:0000 0001 2299 3507)
5 Wayne State University School of Medicine, Center for Molecular Medicine and Genetics, Department of Biochemistry, Microbiology and Immunology, Detroit, USA (GRID:grid.254444.7) (ISNI:0000 0001 1456 7807)
6 University of Michigan, Department of Neurology, Ann Arbor, USA (GRID:grid.214458.e) (ISNI:0000000086837370); University of Michigan, Biophysics Program, Ann Arbor, USA (GRID:grid.214458.e) (ISNI:0000000086837370)
7 University of Michigan Medical School, Department of Molecular & Integrative Physiology, Ann Arbor, USA (GRID:grid.214458.e) (ISNI:0000000086837370); University of Michigan Medical School, Division of Metabolism, Endocrinology & Diabetes, Department of Internal Medicine, Ann Arbor, USA (GRID:grid.214458.e) (ISNI:0000000086837370)